Tipifarnib for HRAS mutations or peripheral T cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial provides access to an experimental drug called tipifarnib for people with certain genetic changes (HRAS mutations) or a type of lymphoma. It is for those who have tried other treatments without success and cannot join other trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed HRAS mutation or a type of lymphoma called peripheral T cell lymphoma (PTCL)
- You are 18 years or older
- You have tried standard treatments that did not work or are not available
- You cannot join any other clinical trial for this drug, for example due to where you live
- You meet other medical criteria decided by the company
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
This trial tests a new drug called GFH276 that targets tumors with a RAS mutation. It aims to see if the drug can shrink or slow these tumors. If you have a solid tumor with this mutation, you may be eligible to participate.
This trial tests a new drug called retlirafusp alfa, which may boost the immune system, when combined with chemotherapy or another drug (fuzuloparib) for people with triple-negative breast cancer that has spread or come back, or is at high risk of coming back. The goal is to see if the combination helps shrink tumors or prevents cancer from returning.
This trial tests a new oral drug, GFH276, in people with advanced lung cancer that has a change in a gene called RAS. The drug is designed to target cancers with this specific mutation, and the study aims to find out if it is safe and effective for patients who have not had prior treatment for their advanced disease.
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
This trial tests a combination of two drugs (toripalimab and anlotinib) with standard chemotherapy for a rare type of skin cancer called dermatofibrosarcoma protuberans (DFSP) that has not responded to the usual treatment (imatinib) or cannot be treated with other options. The goal is to see if this combination can shrink or control the cancer.
Hear when a new HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.